Coyne Terrance P. 4

What Happened Terrance P. Coyne, Executive Vice President & Chief Financial Officer of Royalty Pharma plc (RPRX), received 24,263 Class A Ordinary Shares on May 6, 2026 as the settlement of equity performance awards. The shares were reported as acquired at $0.00 (grant/settlement), so no cash purchase was made.

Key Details

• Transaction date and terms: May 6, 2026 — Award/settlement of 24,263 Class A shares at $0.00.
• Filing date: Form 4 filed May 8, 2026 (reporting the May 6 transaction).
• Shares owned after transaction: Direct post-transaction share total is not specified on this Form 4.
• Notable holdings disclosed in remarks: the reporting person and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares (RPI US Partners 2019, LP) and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,807,277 Class A Ordinary Shares (Class E shares are subject to vesting).
• Footnote: Acquisition is exempt under Rule 16b-3 and relates to settlement of Equity Performance Awards.

Context This was an equity award settlement (compensation), not an open-market purchase or sale — such grants are routine parts of executive pay and do not necessarily signal a personal investment decision. The Rule 16b-3 exemption is a common disclosure for insider compensation-related share issuances. The filing does not indicate any immediate cashless sale or transfer of these shares.